Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.58 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | STK10 | O94804 | 1/20 | 0.42 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.42 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCND2 | P30279 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487580 | 0.89 | NR1H2 (0.54) | NR1H2NR1H3RPS6KA3RPS6KA2SMN1; SMN2 | |
| SCHEMBL3487291 | 0.87 | MAPT (0.48) | NR1H2NR1H3MAPTJAK2MEN1 | |
| SCHEMBL3488372 | 0.86 | NR1H2 (0.53) | NR1H2NR1H3RPS6KA3RPS6KA2SMN1; SMN2 | |
| SCHEMBL3487254 | 0.86 | NR1H2 (0.60) | NR1H2NR1H3RPS6KA3RPS6KA2SMN1; SMN2 | |
| SCHEMBL5606492 | 0.86 | NR1H2 (0.45) | NR1H2NR1H3SMN1; SMN2MAPTMEN1 | |
| SCHEMBL3486886 | 0.84 | NR1H2 (0.58) | NR1H2NR1H3RPS6KA3RPS6KA2SMN1; SMN2 | |
| SCHEMBL3486754 | 0.83 | NR1H2 (0.82) | NR1H2NR1H3RPS6KA3RPS6KA2SMN1; SMN2 | |
| SCHEMBL5607251 | 0.81 | NR1H2 (0.54) | NR1H2NR1H3RPS6KA3RPS6KA2SMN1; SMN2 | |
| SCHEMBL3487282 | 0.80 | NR1H2 (0.46) | NR1H2NR1H3RPS6KA3RPS6KA2SMN1; SMN2 | |
| SCHEMBL3487297 | 0.79 | NR1H2 (0.46) | NR1H2NR1H3RPS6KA3RPS6KA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | claimed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | claimed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1838686-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006073363-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | NR1H2, NR1H3, NR1I2 | NR1H2 1/4885NR1H3 2/4885RPS6KA3 841/4885 |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | NR1H2 1/4885NR1H3 2/4885RPS6KA3 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.